Good days for Indian Pharma ahead?
Good days for Indian Pharma ahead?

Good days for Indian Pharma ahead?

Pratik Shastri Article rating: 3.4

The key reason for this staggered performance was the lack of any strong trigger that could bring certainty in term of revenue. Further, many regulatory hurdles, such as from USFDA, also made things difficult for these companies.

Granules India gets USFDA nod for muscle contraction drugs
Granules India gets USFDA nod for muscle contraction drugs

Granules India gets USFDA nod for muscle contraction drugs

Anthony Fernandes Article rating: 4.2

Granules India informed the bourses on Thursday that its wholly-owned subsidiary, Granules Pharmaceuticals Inc has received approval from the United States Food and Drug Administration (USFDA) for Butalbital, Acetaminophen and Caffeine Capsules USP, 50 mg/300 mg/40 mg.

Aurobindo Pharma gains post ANDA approval
Aurobindo Pharma gains post ANDA approval

Aurobindo Pharma gains post ANDA approval

Anthony Fernandes Article rating: 3.7

The shares of Aurobindo Pharma Limited (APL) were trading in green on Thursday after the company announced that it has received final approval from US Food and Drug Administration (USFDA) to manufacture and market Fluoxetine Tablets, 10 mg and 20 mg.

NIIT launches free ‘remote work excellence kit
NIIT launches free ‘remote work excellence kit

NIIT launches free ‘remote work excellence kit

Rishikesh Gaikwad Article rating: 4.0

NIIT Limited, a global skills and talent development company, on Thursday, announced that it has specially designed and launched NIIT ‘remote work excellence kit’ course to support India’s fight against COVID-19. The online course has been made available absolutely free on its official portal that is, www.niit.com with an aim to facilitate remote working for adults.

Bulls take charge ahead of ‘Good Friday holiday
Bulls take charge ahead of ‘Good Friday holiday

Bulls take charge ahead of ‘Good Friday holiday

Geyatee Deshpande Article rating: 4.8

On Thursday, bulls were again seen establishing their dominance in D-Street as Sensex surged by 4.23 per cent, which is by 1,265.66 points to close at the level of 31,159.62. Nifty also gained by four per cent or 354 points to end the trading week at the level of 9,102.75.

Ten stocks close to their 52-week low
Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Abhishek Kapoor Article rating: 4.0

The market opened in the green on April 9, 2020. The previous trading session witnessed the Sensex going down by 0.6 percent to end at 29,893 and the Nifty was down 0.5 percent to close at 8748.

Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

Abhishek Kapoor Article rating: 3.8

The market opened in the green on April 9, 2020. The previous trading session witnessed the Sensex going down by 0.6 percent to end at 29,893 and the Nifty was down 0.5 percent to close at 8748.

L&T Construction receive power transmission business contracts
L&T Construction receive power transmission business contracts

L&T Construction receive power transmission business contracts

Rishikesh Gaikwad Article rating: 5.0

Power transmission & distribution business of L&T Construction has bagged orders in India and abroad. In Kuwait, a prestigious order has been awarded to upgrade substations and related power facilities in KNPC’s Mina Al Ahmadi oil refinery

RSS
First21872188218921902192219421952196Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR